Stockscreener 앱 받기
6.12
3.01%
-0.19
시간 외 거래:
6.08
-0.04
-0.65%
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis (Nasdaq:ALMS)Stock Analysis - simplywall.st
Why is Alumis stock rallying today? By Investing.com - Investing.com India
Why is Alumis stock rallying today? By Investing.com - Investing.com Canada
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing - marketscreener.com
Wednesday’s top insider buys and sells: NVIDIA leads activity - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Australia
Alumis at Cantor conference: psoriasis strength, lupus setback - investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Canada
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com
Alumis at Cantor conference: psoriasis strength, lupus setback By Investing.com - Investing.com Canada
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com India
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com UK
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Four public talks are planned for September. Alumis will stream them online. - Stock Titan
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - finance.yahoo.com
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Nigeria
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Australia
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com India
Guggenheim downgrades Alumis stock rating after trial miss - investing.com
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com UK
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Nigeria
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com Canada
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com UK
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Nigeria
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com India
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com UK
ALMS Stock Slides After IPO Spike As Traders Reset - StocksToTrade
5.50%
자본화:
|
볼륨(24시간):